Gene therapy has been used successfully to increase levels of the “cold shock protein” in the brains of mice, protecting them against prion disease, researchers have announced.
The discovery by the team from the University of Cambridge, UK, and Freie Universität Berlin, Germany, puts them a step closer towards harnessing the protective effects of cooling the brain to treat patients with acute brain injury. There is also potential to prevent dementia, they believe.
When the body cools down significantly, it increases its levels of RBM3, the “cold shock protein”, which helps to protect the brain from damage.
In 2015, Professor Giovanna Mallucci, from Cambridge, and colleagues showed that in mice RBM3 can protect the brain against damage associated with build-up of misfolded proteins, which can lead to various forms of dementia and from prion diseases.
Although induced hypothermia is used to treat patients in intensive care units, there are associated risks, such as blood clotting and pneumonia.
For this study, published in EMBO Molecular Medicine, scientists at the UK Dementia Research Institute at the University of Cambridge, and the Institute of Chemistry and Biochemistry at Freie Universität Berlin, looked to see if antisense oligonucleotides (ASOs), a type of gene therapy, could increase levels of the cold shock protein in the brains of mice and protect them.
They examined the gene that codes production of the cold shock protein and found it contains a key element which, under normal conditions, prevents its expression. However, removing or decreasing this element using an ASO creates a long-lasting boost to RBM3 production.
Using mice infected with prions, some were injected with a single dose of the ASO, while the others were given a control treatment.
After 12 weeks, the mice that had received the control treatment showed extensive loss of neurons in the hippocampus, but the mice that had had the ASO had RBM3 levels that were twice as high as in the other mice, with seven of the eight ASO-treated mice showing extensive preservation of neurons in the hippocampus.
Professor Mallucci, who led the work while at the UK Dementia Research Institute at the University of Cambridge, said: “Essentially, the cold shock protein enables the brain to protect itself – in this case, against the damage to nerve cells in the brain during prion disease. Remarkably, we showed that just a single injection with the ASO was sufficient to provide long-lasting protection for these mice, preventing the inevitable progression of neurodegeneration.”
Professor Florian Heyd from Freie Universität Berlin added: “This approach offers the prospect of being able to protect against diseases such as Alzheimer’s and Parkinson’s disease, for which we have no reliable preventative treatments.
“We are still a long way off this stage as our work was in mice, but if we can safely use ASOs to boost production of the cold shock protein in humans, it might be possible to prevent dementia. We are already seeing ASOs being used to successfully treat spinal muscular atrophy and they have recently been licensed to treat motor neurone disease.”
Preußner M, Smith HL, Hughes D et al. ASO targeting temperature-controlled RBM3 poison exon splicing prevents neurodegeneration in vivo. EMBO Molecular Medicine 22 March 2023

Leave a Reply